Guelph, ON—Nutrasource Pharmaceutical and Nutraceutical Services shared news of a collaborative study evaluating the tolerability of supplementation of cannabidiol (CBD) on healthy dogs. 

The National Animal Supplement Council (NASC) shared positive results of the research showing the tolerability of broad spectrum cannabidiol (CBD), broad spectrum CBD with cannabigerol (CBG) and broad-spectrum CBD with cannabidiolic acid (CBDA) in healthy male and female dogs when given a daily dose for 90 consecutive days. The study has been submitted for peer-review.

Nutrasource noted that consumer trends show growth towards supplements for pet’s overall health. Pet owners are increasingly turning to CBD products to help support and maintain pets’ quality of life. Such products have been shown to have a variety of benefits.   

“Part of what makes this study unique is the data from support from the NASC’s Adverse Event Reporting System (NAERS), which is the most advanced system of post market surveillance in the world,” said Bill Bookout, President of NASC, in a press release. “Through this system, NASC members enter their products, ingredients, administration recommendations into the NAERS database along with the number of units in each container provided to customers. These collective data are processed by algorithms in the system and Adverse Events, both serious and non-serious can be compared and analyzed per million administrations.” 

About the research

The randomized, non-blinded, negative controlled, parallel design repeat dose study looked at healthy dogs (16 males and 16 females) at least 6-months of age. The dogs were randomly placed into four groups and given either medium chain triglyceride oil as the control or one of the following at 5 mg total cannabinoids/kg body weight/day for 90 consecutive days:

  • a broad spectrum CBD
  • a broad spectrum CBD with CBG
  • a broad spectrum CBD with CBDA

Animals were observed daily with detailed clinical examinations conducted weekly. Body weights, food consumption and clinical pathology evaluations also were included in the study. 

Results showed that cannabinoids were well tolerated when healthy male and female dogs were dosed for 90 consecutive days. No serious adverse events were reported during the study.

Post-market surveillance data for hemp-derived supplement products sold for use in dogs from 2010 to April 2023 shows that the rate per 1 million administrations sold is 2.19 and 0.01, for adverse events and serious adverse events, respectively, Nutrasource reported.  Based on the available data, the study authors concluded that these substances do not pose significant risk to dogs in long-term use.

"This research is a game-changer for pet health offering an expanded horizon for veterinarians, industry, and pet owners alike," said Nutrasource Director of Preclinical and Companion Animal Services, Dr. Margitta Dziwenka, DVM, DABT. "These findings grant us a renewed sense of confidence in exploring CBD product development for use in companion animals, so that industry can confidently answer the call and growing demand for natural and alternative products.”